Originally published by our sister publication Specialty Pharmacy Continuum
The FDA approved the citrate-free, high-concentration (100 mg/mL) formulation of adalimumab-bwwd (Hadlima, Samsung Bioepis), a biosimilar referencing Humira (adalimumab, AbbVie).
Adalimumab-bwwd, a tumor necrosis factor (TNF), will be available in prefilled syringe and autoinjector options, and the autoinjector was specifically designed with the patient in mind. The biosimilar was approved previously by